RxDoctor Payments Data

Tammy Milholen

Family · Lexington, TNNPI 1093039000

Payments from drug & device makers

$2,465in general payments, 2019–2025

Across 128 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$644
  • AbbVie$512
  • AstraZeneca$333
  • Amgen$226
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$163
  • Pfizer$108
  • plus $479 from 14 others

What the payments were for

  • Food & beverage$2,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,465 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$147,798
TrulicityDulaglutide67$81,711
JardianceEmpagliflozin61$66,311
EliquisApixaban64$49,997
JanuviaSitagliptin Phosphate28$33,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,569
FarxigaDapagliflozin Propanediol21$20,200
Tresiba Flextouch U-100Insulin Degludec25$16,822
LinzessLinaclotide22$15,709
Repatha SureclickEvolocumab20$14,921
MounjaroTirzepatide14$14,915
XareltoRivaroxaban22$12,821
MyrbetriqMirabegron17$11,914
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,199
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$8,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$644$150,004148 claims
Lilly USA, LLCTrulicity, Mounjaro$62$96,62681 claims
Boehringer IngelheimJardiance$60$66,31161 claims
PfizerEliquis$108$49,99764 claims
AstraZenecaFarxiga, Breztri Aerosphere$333$29,39833 claims
GSKTrelegy Ellipta$42$20,56927 claims
AbbVieLinzess$512$15,70922 claims
Johnson & JohnsonXarelto$42$12,82122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Lexington

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →